A rat study finds exenatide speeds facial nerve recovery

The researchers divided 28 female Sprague-Dawley rats into four groups: a control group, a sham group that did not receive the nerve crush, and two exenatide groups that received 2.5 or 10 micrograms per rat per day for 14 days ¹. Exenatide was injected under the skin. All groups except the sham group had a crush injury applied to the left facial nerve ¹.

The clearest functional finding was movement. The 10 microgram group had a higher blink reflex score at week 1. By weeks 3 and 4, whisker movement scores were higher in exenatide-treated rats than in untreated rats ¹. Electrical nerve tests at weeks 2 and 4 showed higher amplitude values and shorter latency periods in the exenatide groups, which means the recovering nerve produced stronger and faster signals ¹.

The tissue changes pointed in the same direction. Exenatide-treated rats had a lower rate of severe macrovacuolation, a sign of cell injury, and greater myelin thickness, the protective coating around nerve fibers ¹. The authors concluded that exenatide treatment had a positive and accelerating effect on facial nerve recovery in traumatic facial paralysis ¹.

The nerve tissue assessment looked at two markers of damage. Macrovacuolation means large empty spaces inside nerve cells, which often appear when a facial nerve is badly stressed. Severe macrovacuolation was less common in the exenatide groups than in the control group ¹. Myelin is the fatty wrapping that helps electrical signals travel along a nerve. The exenatide groups had thicker myelin, suggesting better repair of the nerve coating ¹.

The vascular response also differed. Exenatide reduced the severity of vasoconstriction, a tightening of blood vessels that can limit repair, and the effect was dose-dependent ¹. A dose-dependent effect means the higher dose produced a larger change. The researchers reported that this effect was statistically significant ¹.

These are early animal findings. A rat facial nerve crush is not the same as facial paralysis or nerve damage in people, and 14 days of treatment is a short window. Still, the study measured functional, electrical, and tissue outcomes, and all three showed changes in the same direction ¹.

A separate 2026 systematic review collected 66 animal studies on glucagon-like peptide-1 (GLP-1) receptor agonists and reward behavior ². The review found that exenatide, when administered locally in selected brain regions, reduced substance use, food seeking, and sexual behaviors in the animal models ². liraglutide attenuated substance and food-related rewards, semaglutide reduced substance and sucrose intake, and dulaglutide reduced substance intake ².

These findings point in one direction. GLP-1 receptor agonists tend to reduce reward-associated behaviors in rodents. The review included food, drug, and sexual reward. It does not establish a human effect or a clinical use, but it helps explain why these medicines are being studied for conditions that involve reward processing ².

A third 2026 report looked at hearing and balance adverse-event reports for GLP-1 receptor agonists in the US Food and Drug Administration Adverse Event Monitoring System through the first quarter of 2026 ³. The analysis identified 1,950 unique reports. Exenatide appeared in 576 reports, dulaglutide in 622, semaglutide in 559, and liraglutide in 192 ³. The most common reported problems were hypoacusis, which means reduced hearing, vertigo, tinnitus, and deafness ³.

The reporting patterns were not the same across drugs. Dulaglutide reports were enriched for hypoacusis, while liraglutide and semaglutide reports were enriched for vertigo and tinnitus ³. Exenatide was one of the four adequately represented agents in the comparison, but the reported enrichment statements focused on dulaglutide, liraglutide, and semaglutide ³. The median time to onset (half of reports were sooner, half later) was 3 days, although valid dates were available for only 19.3 percent of reports ³.

The authors are clear that these database counts are hypothesis-generating. They do not establish how often these problems occur, whether one drug is safer than another, or whether any drug caused the reports ³.

This table puts the three new sources next to each other. One is an experimental nerve study, one is a review of existing animal reward experiments, and one is a database pattern. They do not measure the same thing. The rat study provides direct exenatide-specific evidence for facial nerve recovery ¹. The review and database analysis are broader and cannot confirm cause and effect ².

Exenatide already has a long research record in glucose control and weight, but nerve recovery is a newer direction. Its established effects include reductions in HbA1c (a three-month average blood sugar measure) and modest weight loss in diabetes trials ⁴. The new nerve study is preclinical, so it sits beside the rodent work showing exendin-4 reduces alcohol and stimulant reward ⁶. The reward review strengthens that pattern across 66 studies ².

The hearing and balance data add to the known fact that GLP-1 receptor agonists can affect many body systems beyond glucose. The exenatide page already notes injection-site reactions and pancreatic and biliary questions ⁸. This new report does not change the approved use, which remains glucose control in type 2 diabetes ¹⁰.

The rat finding is early. The study used a small group of 28 rats and only 14 days of treatment. It did not test human facial nerve injuries, and it did not compare exenatide with another GLP-1 receptor agonist ¹. The reward review is animal-based, so it cannot say whether exenatide changes human substance use or food reward ². The audiovestibular database analysis cannot measure how common these problems are or whether exenatide causes them ³.